Hyperlipoproteinemia(a): clinical significance and treatment options

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Genetic Epidemiology

Background:

• Epidemiologic and Mendelian randomization studies suggest lipoprotein(a) (Lp(a)) has a causal role in atherosclerosis and cardiovascular disease (CVD).
• The association between Lp(a) levels and CVD risk is continuous, without a clear threshold, with concentrations of 60 mg/dl linked to a 1.5-fold increased odds of coronary heart disease.
• Elevated Lp(a) is a significant, yet often unaddressed, cardiovascular risk factor.

Purpose of the Study:

• To review the current understanding of lipoprotein(a)'s role in cardiovascular disease pathogenesis.
• To evaluate existing and potential therapeutic strategies for lowering Lp(a) levels.
• To highlight the need for clinical trials demonstrating the efficacy of Lp(a) reduction on cardiovascular outcomes.

Main Methods:

• Review of recent epidemiologic and Mendelian randomization studies.
• Analysis of current pharmacological and non-pharmacological interventions for Lp(a) management.
• Assessment of lipoprotein apheresis as a treatment option.

Main Results:

• Niacin (nicotinic acid) is the only pharmacologic agent shown to decrease Lp(a), but it is often poorly tolerated.
• Diet, exercise, statins, fibrates, and ezetimibe do not affect Lp(a) levels.
• Lipoprotein apheresis effectively reduces Lp(a) but is costly, impractical for most, and dependent on healthcare systems.
• No current treatment selectively lowers Lp(a) without affecting other lipoproteins.

Conclusions:

• Despite strong evidence linking Lp(a) to CVD, no treatment has been proven to reduce cardiovascular endpoints by lowering Lp(a).
• There is an urgent need for rigorously designed randomized trials to establish the clinical benefit of reducing Lp(a) concentrations.
• Developing selective and well-tolerated therapies to lower Lp(a) is crucial for managing cardiovascular risk.